Nektar Therapeutics (NKTR) Tops Q1 EPS by 9c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $74.02 -0.68%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.14), $0.09 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $58.9 million versus the consensus estimate of $43.78 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- BMO starts chip stocks coverage: Here are its preferred picks
- Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
